10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ABOS (Acumen Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Acumen Pharmaceuticals Inc together

I guess you are interested in Acumen Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Acumen Pharmaceuticals Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Acumen Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Acumen Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Acumen Pharmaceuticals Inc

I send you an email if I find something interesting about Acumen Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Acumen Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Acumen Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.57
Expected worth in 1 year
$0.81
How sure are you?
9.5%

+ What do you gain per year?

Total Gains per Share
$-1.76
Return On Investment
-151.6%

For what price can you sell your share?

Current Price per Share
$1.16
Expected price per share
$1.09 - $1.48
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acumen Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.16
Intrinsic Value Per Share
$-27.79 - $-33.03
Total Value Per Share
$-25.23 - $-30.46

2.2. Growth of Acumen Pharmaceuticals Inc (5 min.)




Is Acumen Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$155.5m$244.5m-$44.9m-22.5%

How much money is Acumen Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$29m-$13.9m-$15m-51.9%
Net Profit Margin0.0%-1,422.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Acumen Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#282 / 884

Most Revenue
#837 / 884

Most Profit
#699 / 884

Most Efficient
#361 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acumen Pharmaceuticals Inc?

Welcome investor! Acumen Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Acumen Pharmaceuticals Inc.

First you should know what it really means to hold a share of Acumen Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Acumen Pharmaceuticals Inc is $1.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acumen Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acumen Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.57. Based on the TTM, the Book Value Change Per Share is $-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is $0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acumen Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.48-41.0%-0.48-41.4%-0.23-19.9%-0.30-25.8%-0.27-23.6%-0.26-22.7%
Usd Book Value Change Per Share-0.43-37.4%-0.44-37.9%0.3429.5%-0.08-7.2%0.1311.1%0.1210.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-37.4%-0.44-37.9%0.3429.5%-0.08-7.2%0.1311.1%0.1210.5%
Usd Price Per Share1.10-1.93-4.21-4.06-3.71-3.54-
Price to Earnings Ratio-0.58--1.08--4.69--4.67--6.63--6.31-
Price-to-Total Gains Ratio-2.53--4.80--23.36--22.57--22.96--22.96-
Price to Book Ratio0.43-0.57-1.11-1.19-1.05-1.00-
Price-to-Total Gains Ratio-2.53--4.80--23.36--22.57--22.96--22.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.16
Number of shares862
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.440.13
Usd Total Gains Per Share-0.440.13
Gains per Quarter (862 shares)-378.94110.66
Gains per Year (862 shares)-1,515.75442.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1516-15260443433
20-3032-30420885876
30-4547-4558013281319
40-6063-6074017711762
50-7579-7590022132205
60-9095-9106026562648
70-10610-10622030983091
80-12126-12138035413534
90-13642-13654039843977
100-15158-15170044264420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.016.02.010.0%2.016.03.09.5%2.016.03.09.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.016.02.010.0%2.016.03.09.5%2.016.03.09.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Acumen Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.434-0.440+1%0.342-227%-0.083-81%0.128-438%0.122-455%
Book Value Per Share--2.5673.296-22%4.037-36%3.505-27%2.519+2%2.399+7%
Current Ratio--8.02210.569-24%25.647-69%21.016-62%25.058-68%23.865-66%
Debt To Asset Ratio--0.2390.205+17%0.084+183%0.108+121%0.365-34%0.347-31%
Debt To Equity Ratio--0.3150.261+21%0.096+229%0.131+140%0.081+288%0.077+308%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--166821740.000262068662.000-36%445074197.500-63%414466498.667-60%472846259.067-65%472846259.067-65%
Eps---0.475-0.480+1%-0.231-51%-0.299-37%-0.274-42%-0.263-45%
Ev To Ebitda Ratio---1.373-2.538+85%-8.191+496%-7.410+440%-12.540+813%-12.540+813%
Free Cash Flow Per Share---0.565-0.423-25%-0.210-63%-0.262-54%-0.184-67%-0.176-69%
Free Cash Flow To Equity Per Share---0.565-0.424-25%0.446-227%-0.039-93%0.231-344%0.244-332%
Gross Profit Margin--1.0001.0010%1.0010%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---33.029----------
Intrinsic Value_10Y_min---27.795----------
Intrinsic Value_1Y_max---1.378----------
Intrinsic Value_1Y_min---1.352----------
Intrinsic Value_3Y_max---5.612----------
Intrinsic Value_3Y_min---5.328----------
Intrinsic Value_5Y_max---11.621----------
Intrinsic Value_5Y_min---10.660----------
Market Cap70265144.000+5%66630740.000116906662.000-43%255165447.500-74%246129915.333-73%224999894.300-70%214285613.619-69%
Net Profit Margin----0%-14.2220%-4.7410%-3.7150%-3.9690%
Operating Margin----0%-11.6470%-3.8820%-4.1120%-4.3470%
Operating Ratio----0%15.936-100%5.312-100%5.057-100%5.727-100%
Pb Ratio0.452+5%0.4280.573-25%1.107-61%1.191-64%1.053-59%1.003-57%
Pe Ratio-0.610-5%-0.578-1.081+87%-4.693+711%-4.674+708%-6.625+1045%-6.310+991%
Price Per Share1.160+5%1.1001.930-43%4.213-74%4.063-73%3.715-70%3.538-69%
Price To Free Cash Flow Ratio-0.514-5%-0.487-1.296+166%-5.381+1005%-5.614+1053%-6.583+1252%-6.270+1187%
Price To Total Gains Ratio-2.672-5%-2.534-4.800+89%-23.359+822%-22.572+791%-22.955+806%-22.955+806%
Quick Ratio--13.90218.252-24%41.706-67%31.775-56%35.124-60%33.452-58%
Return On Assets---0.141-0.120-15%-0.053-62%-0.076-46%-0.125-11%-0.119-16%
Return On Equity---0.185-0.153-18%-0.058-68%-0.089-52%-0.096-48%-0.108-42%
Total Gains Per Share---0.434-0.440+1%0.342-227%-0.083-81%0.128-438%0.122-455%
Usd Book Value--155521000.000199621500.000-22%244538500.000-36%212305833.333-27%152608500.000+2%145341428.571+7%
Usd Book Value Change Per Share---0.434-0.440+1%0.342-227%-0.083-81%0.128-438%0.122-455%
Usd Book Value Per Share--2.5673.296-22%4.037-36%3.505-27%2.519+2%2.399+7%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--166821740.000262068662.000-36%445074197.500-63%414466498.667-60%472846259.067-65%472846259.067-65%
Usd Eps---0.475-0.480+1%-0.231-51%-0.299-37%-0.274-42%-0.263-45%
Usd Free Cash Flow---34200000.000-25640250.000-25%-12695000.000-63%-15876833.333-54%-11123250.000-67%-10680047.619-69%
Usd Free Cash Flow Per Share---0.565-0.423-25%-0.210-63%-0.262-54%-0.184-67%-0.176-69%
Usd Free Cash Flow To Equity Per Share---0.565-0.424-25%0.446-227%-0.039-93%0.231-344%0.244-332%
Usd Market Cap70265144.000+5%66630740.000116906662.000-43%255165447.500-74%246129915.333-73%224999894.300-70%214285613.619-69%
Usd Price Per Share1.160+5%1.1001.930-43%4.213-74%4.063-73%3.715-70%3.538-69%
Usd Profit---28796000.000-29063000.000+1%-13984250.000-51%-17956000.000-38%-16520500.000-43%-15831190.476-45%
Usd Revenue----0%72500.000-100%24166.667-100%130350.000-100%134904.762-100%
Usd Total Gains Per Share---0.434-0.440+1%0.342-227%-0.083-81%0.128-438%0.122-455%
 EOD+5 -3MRQTTM+11 -22YOY+5 -303Y+5 -305Y+9 -2610Y+9 -26

3.3 Fundamental Score

Let's check the fundamental score of Acumen Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.610
Price to Book Ratio (EOD)Between0-10.452
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.902
Current Ratio (MRQ)Greater than18.022
Debt to Asset Ratio (MRQ)Less than10.239
Debt to Equity Ratio (MRQ)Less than10.315
Return on Equity (MRQ)Greater than0.15-0.185
Return on Assets (MRQ)Greater than0.05-0.141
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Acumen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.763
Ma 20Greater thanMa 501.173
Ma 50Greater thanMa 1001.093
Ma 100Greater thanMa 2001.148
OpenGreater thanClose1.150
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-18 22:10:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acumen Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,422.2%+1,422.2%
TTM-5Y-371.5%+371.5%
5Y-371.5%10Y-396.9%+25.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--139.0%+139.0%
YOY-1,422.2%-194.4%-1,227.8%
3Y-474.1%-248.5%-225.6%
5Y-371.5%-343.3%-28.2%
10Y-396.9%-488.9%+92.0%
4.3.1.2. Return on Assets

Shows how efficient Acumen Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • -14.1% Return on Assets means that Acumen Pharmaceuticals Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acumen Pharmaceuticals Inc:

  • The MRQ is -14.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.1%TTM-12.0%-2.1%
TTM-12.0%YOY-5.3%-6.6%
TTM-12.0%5Y-12.5%+0.5%
5Y-12.5%10Y-11.9%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.1%-11.6%-2.5%
TTM-12.0%-11.7%-0.3%
YOY-5.3%-11.4%+6.1%
3Y-7.6%-11.9%+4.3%
5Y-12.5%-12.1%-0.4%
10Y-11.9%-13.8%+1.9%
4.3.1.3. Return on Equity

Shows how efficient Acumen Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • -18.5% Return on Equity means Acumen Pharmaceuticals Inc generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acumen Pharmaceuticals Inc:

  • The MRQ is -18.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.5%TTM-15.3%-3.2%
TTM-15.3%YOY-5.8%-9.4%
TTM-15.3%5Y-9.6%-5.7%
5Y-9.6%10Y-10.8%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.5%-13.5%-5.0%
TTM-15.3%-15.0%-0.3%
YOY-5.8%-14.5%+8.7%
3Y-8.9%-16.9%+8.0%
5Y-9.6%-17.9%+8.3%
10Y-10.8%-19.9%+9.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Acumen Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acumen Pharmaceuticals Inc is operating .

  • Measures how much profit Acumen Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,164.7%+1,164.7%
TTM-5Y-411.2%+411.2%
5Y-411.2%10Y-434.7%+23.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.7%+249.7%
YOY-1,164.7%-208.4%-956.3%
3Y-388.2%-221.7%-166.5%
5Y-411.2%-344.1%-67.1%
10Y-434.7%-470.4%+35.7%
4.3.2.2. Operating Ratio

Measures how efficient Acumen Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY15.936-15.936
TTM-5Y5.057-5.057
5Y5.05710Y5.727-0.670
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM-2.680-2.680
YOY15.9363.080+12.856
3Y5.3123.621+1.691
5Y5.0574.734+0.323
10Y5.7276.546-0.819
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Acumen Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.02 means the company has $8.02 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 8.022. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.569. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.022TTM10.569-2.547
TTM10.569YOY25.647-15.077
TTM10.5695Y25.058-14.489
5Y25.05810Y23.865+1.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.0223.659+4.363
TTM10.5693.834+6.735
YOY25.6474.141+21.506
3Y21.0164.661+16.355
5Y25.0585.756+19.302
10Y23.8656.151+17.714
4.4.3.2. Quick Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 13.90 means the company can pay off $13.90 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 13.902. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.252. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.902TTM18.252-4.351
TTM18.252YOY41.706-23.454
TTM18.2525Y35.124-16.872
5Y35.12410Y33.452+1.673
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.9022.799+11.103
TTM18.2523.143+15.109
YOY41.7063.794+37.912
3Y31.7754.307+27.468
5Y35.1245.707+29.417
10Y33.4526.457+26.995
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Acumen Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acumen Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acumen Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Acumen Pharmaceuticals Inc assets are financed with 23.9% credit (debt) and the remaining percentage (100% - 23.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.239. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.205. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.239TTM0.205+0.034
TTM0.205YOY0.084+0.121
TTM0.2055Y0.365-0.160
5Y0.36510Y0.347+0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2390.324-0.085
TTM0.2050.347-0.142
YOY0.0840.329-0.245
3Y0.1080.340-0.232
5Y0.3650.349+0.016
10Y0.3470.379-0.032
4.5.4.2. Debt to Equity Ratio

Measures if Acumen Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.5% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acumen Pharmaceuticals Inc:

  • The MRQ is 0.315. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.261. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.261+0.054
TTM0.261YOY0.096+0.165
TTM0.2615Y0.081+0.180
5Y0.08110Y0.077+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3150.379-0.064
TTM0.2610.435-0.174
YOY0.0960.412-0.316
3Y0.1310.446-0.315
5Y0.0810.460-0.379
10Y0.0770.509-0.432
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acumen Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Acumen Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.58 means the investor is paying $-0.58 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is -0.610. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.578. Based on the earnings, the company is expensive. -2
  • The TTM is -1.081. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.610MRQ-0.578-0.032
MRQ-0.578TTM-1.081+0.503
TTM-1.081YOY-4.693+3.612
TTM-1.0815Y-6.625+5.544
5Y-6.62510Y-6.310-0.315
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.610-2.282+1.672
MRQ-0.578-2.062+1.484
TTM-1.081-2.541+1.460
YOY-4.693-3.722-0.971
3Y-4.674-3.754-0.920
5Y-6.625-6.100-0.525
10Y-6.310-6.653+0.343
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is -0.514. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.487. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.296. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.514MRQ-0.487-0.027
MRQ-0.487TTM-1.296+0.809
TTM-1.296YOY-5.381+4.084
TTM-1.2965Y-6.583+5.287
5Y-6.58310Y-6.270-0.313
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.514-3.101+2.587
MRQ-0.487-2.689+2.202
TTM-1.296-3.594+2.298
YOY-5.381-4.363-1.018
3Y-5.614-5.065-0.549
5Y-6.583-8.478+1.895
10Y-6.270-9.273+3.003
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acumen Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.43 means the investor is paying $0.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acumen Pharmaceuticals Inc:

  • The EOD is 0.452. Based on the equity, the company is cheap. +2
  • The MRQ is 0.428. Based on the equity, the company is cheap. +2
  • The TTM is 0.573. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.452MRQ0.428+0.023
MRQ0.428TTM0.573-0.145
TTM0.573YOY1.107-0.534
TTM0.5735Y1.053-0.480
5Y1.05310Y1.003+0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4521.932-1.480
MRQ0.4281.848-1.420
TTM0.5732.119-1.546
YOY1.1072.469-1.362
3Y1.1912.526-1.335
5Y1.0533.667-2.614
10Y1.0034.351-3.348
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acumen Pharmaceuticals Inc.

4.8.1. Institutions holding Acumen Pharmaceuticals Inc

Institutions are holding 72.199% of the shares of Acumen Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31RA Capital Management, LLC24.65120.27431493206300
2025-03-31Sands Capital Ventures, LLC5.64120.9193341707500
2025-03-31Franklin Resources Inc5.1870.0013141939-131694-4.0229
2025-03-31BlackRock Inc3.84830.00012331049-40998-1.7284
2025-03-31FMR Inc3.34410.0001202562318630.0921
2025-03-31Vanguard Group Inc3.197801936991-3780-0.1948
2025-03-31Knollwood Investment Advisory LLC2.68850.198162851000
2025-03-31Millennium Management LLC1.87410.00071135222-209523-15.5809
2025-03-31Pathstone Holdings LLC1.79370.0052108653147968679.0459
2025-03-31Alyeska Investment Group, L.P.1.55120.004193960300
2025-03-31LAURION CAPITAL MANAGEMENT LP1.43140.02486704600
2025-03-31Geode Capital Management, LLC1.42290.0001861899-8656-0.9943
2025-03-31JPMorgan Chase & Co1.3740.0001832267-105641-11.2635
2025-03-31Hudson Bay Capital Management LP1.27120.0026770000550007.6923
2025-03-31State Street Corp0.86050521206-4600-0.8748
2025-03-31Two Sigma Advisers, LLC0.76550.0012463700-35400-7.0928
2025-03-31Northern Trust Corp0.47850.0001289836-17779-5.7796
2025-03-31Ikarian Capital, LLC0.43880.03626576900
2025-03-31Renaissance Technologies Corp0.42380.0004256700-513-0.1994
2025-03-31Two Sigma Investments LLC0.38350.0006232293-68975-22.8949
Total 62.62721.467937935322-91010-0.2%

4.9.2. Funds holding Acumen Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Franklin Biotechnology Discv A(acc)USD2.4410.1206147858600
2024-09-30Franklin Small Cap Growth SMA1.96140.1053118809111880910
2025-04-30Vanguard Total Stock Mkt Idx Inv1.89240.0001114631600
2025-04-30Fidelity Select Health Care1.8820.0208114000000
2025-05-31iShares Russell 2000 ETF1.60430.001697180300
2025-04-30Franklin Biotechnology Discovery A1.36430.131882640000
2025-04-30Franklin Small Cap Growth Adv1.26780.03876797200
2025-03-31Franklin US Small Cap Growth Equity1.26780.0368767972-128219-14.3071
2025-04-30Fidelity Advisor Health Care I1.15560.022270000000
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.77950.000547217200
2025-03-31Fidelity Small Cap Index0.67530.0019409028-13338-3.1579
2025-05-31iShares Russell 2000 Value ETF0.60150.003536432300
2025-05-31A4Investments SICAV SIF ACCI IlanaA2EURH0.37155.669322500000
2025-04-30Vanguard Russell 2000 ETF0.34250.002207479115155.8761
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.33880.002420520000
2025-04-30Fidelity VIP Health Care Initial0.29720.020418000000
2025-04-30Fidelity Extended Market Index0.2830.0005171435-1639-0.947
2025-02-28Vifag 2002 SICAV0.24760.27915000000
2025-04-30Schwab Small Cap Index0.1930.002311690200
2025-03-31Bridgeway Ultra-Small Company Market0.16820.1144101871-30129-22.825
Total 19.13476.573411590550+1026281+8.9%

5.3. Insider Transactions

Insiders are holding 11.499% of the shares of Acumen Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-23Matt ZugaSELL289021.72
2025-01-21Daniel Joseph OconnellSELL126191.59
2025-01-21Eric SiemersSELL32191.59
2025-01-21Matt ZugaSELL43641.6
2025-01-21Russell BartonSELL29141.61
2025-01-03Daniel Joseph OconnellSELL477781.84
2025-01-03Eric SiemersSELL108591.85
2025-01-03Matt ZugaSELL132351.84
2025-01-03Russell BartonSELL76361.86
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets204,478
Total Liabilities48,957
Total Stockholder Equity155,521
 As reported
Total Liabilities 48,957
Total Stockholder Equity+ 155,521
Total Assets = 204,478

Assets

Total Assets204,478
Total Current Assets154,947
Long-term Assets49,531
Total Current Assets
Cash And Cash Equivalents 30,159
Short-term Investments 118,989
Net Receivables 376
Other Current Assets 5,423
Total Current Assets  (as reported)154,947
Total Current Assets  (calculated)154,947
+/-0
Long-term Assets
Property Plant Equipment 373
Long Term Investments 48,795
Intangible Assets 56
Long-term Assets Other 307
Long-term Assets  (as reported)49,531
Long-term Assets  (calculated)49,531
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,315
Long-term Liabilities29,642
Total Stockholder Equity155,521
Total Current Liabilities
Short-term Debt 138
Accounts payable 1,056
Other Current Liabilities 18,121
Total Current Liabilities  (as reported)19,315
Total Current Liabilities  (calculated)19,315
+/-0
Long-term Liabilities
Long term Debt 28,748
Capital Lease Obligations 252
Long-term Liabilities  (as reported)29,642
Long-term Liabilities  (calculated)29,000
+/- 642
Total Stockholder Equity
Common Stock6
Retained Earnings -353,923
Accumulated Other Comprehensive Income 15
Other Stockholders Equity 509,423
Total Stockholder Equity (as reported)155,521
Total Stockholder Equity (calculated)155,521
+/-0
Other
Capital Stock6
Cash and Short Term Investments 149,148
Common Stock Shares Outstanding 60,526
Liabilities and Stockholders Equity 204,478
Net Debt -1,159
Net Invested Capital 184,269
Net Working Capital 135,632
Property Plant and Equipment Gross 373
Short Long Term Debt Total 29,000



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
44,429
42,373
72,943
234,849
230,330
220,087
211,678
203,264
196,587
187,864
177,405
286,371
310,125
300,967
288,913
266,975
238,992
204,478
204,478238,992266,975288,913300,967310,125286,371177,405187,864196,587203,264211,678220,087230,330234,84972,94342,37344,429000
   > Total Current Assets 
6,552
0
0
44,429
42,103
70,572
204,913
198,661
192,098
191,053
202,560
180,329
144,032
149,538
218,598
246,615
255,831
266,915
207,632
178,306
154,947
154,947178,306207,632266,915255,831246,615218,598149,538144,032180,329202,560191,053192,098198,661204,91370,57242,10344,429006,552
       Cash And Cash Equivalents 
-6,552
0
0
43,777
41,407
68,812
135,802
122,162
108,764
111,067
157,540
130,101
77,999
77,248
94,917
66,886
46,930
67,955
33,184
35,627
30,159
30,15935,62733,18467,95546,93066,88694,91777,24877,999130,101157,540111,067108,764122,162135,80268,81241,40743,77700-6,552
       Short-term Investments 
13,104
0
0
0
0
0
64,162
72,075
80,326
78,844
42,654
47,504
62,410
67,633
120,517
176,636
205,582
192,517
167,159
135,930
118,989
118,989135,930167,159192,517205,582176,636120,51767,63362,41047,50442,65478,84480,32672,07564,1620000013,104
       Net Receivables 
0
0
0
109
109
109
109
96
158
162
1,867
1,305
0
2,710
0
225
189
106
319
398
376
37639831910618922502,71001,3051,86716215896109109109109000
       Other Current Assets 
0
0
0
543
1,004
1,651
4,840
4,424
3,008
1,142
2,366
2,724
3,623
4,657
3,164
2,868
3,130
6,337
7,289
6,351
5,423
5,4236,3517,2896,3373,1302,8683,1644,6573,6232,7242,3661,1423,0084,4244,8401,6511,004543000
   > Long-term Assets 
-6,552
0
0
0
270
2,371
29,936
31,669
27,989
20,625
704
16,258
43,832
27,867
67,773
63,510
45,136
21,998
59,343
60,686
49,531
49,53160,68659,34321,99845,13663,51067,77327,86743,83216,25870420,62527,98931,66929,9362,371270000-6,552
       Property Plant Equipment 
0
0
0
0
0
6
13
36
252
280
275
270
218
165
125
503
470
430
385
339
373
3733393854304705031251652182702752802523613600000
       Long Term Investments 
0
0
0
0
0
0
29,910
31,619
27,658
20,001
0
15,837
43,419
27,311
67,270
62,553
44,108
20,908
58,552
59,968
48,795
48,79559,96858,55220,90844,10862,55367,27027,31143,41915,837020,00127,65831,61929,910000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
186
184
0
75
56
567501841860000000000000000
       Long-term Assets Other 
-6,552
0
0
0
270
2,365
13
14
79
344
429
151
195
391
378
454
558
476
406
379
307
3073794064765584543783911951514293447914132,365270000-6,552
       Deferred Long Term Asset Charges 
0
0
0
0
0
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,35200000
> Total Liabilities 
0
0
0
63,020
87,835
179,022
1,489
5,147
3,998
5,159
6,613
7,812
8,779
8,531
6,098
43,152
38,933
44,966
49,773
57,176
48,957
48,95757,17649,77344,96638,93343,1526,0988,5318,7797,8126,6135,1593,9985,1471,489179,02287,83563,020000
   > Total Current Liabilities 
0
0
0
6,367
31,182
4,518
1,489
5,147
3,936
5,134
6,613
7,812
8,779
8,531
6,098
12,971
8,472
15,367
19,914
27,607
19,315
19,31527,60719,91415,3678,47212,9716,0988,5318,7797,8126,6135,1343,9365,1471,4894,51831,1826,367000
       Short-term Debt 
0
0
0
0
0
0
0
0
278
284
266
210
134
58
4
1,732
242
250
129
266
138
1382661292502421,73245813421026628427800000000
       Accounts payable 
0
0
0
531
918
2,907
382
1,088
1,219
1,710
2,084
1,640
762
2,026
1,362
1,379
3,079
4,211
2,342
5,648
1,056
1,0565,6482,3424,2113,0791,3791,3622,0267621,6402,0841,7101,2191,0883822,907918531000
       Other Current Liabilities 
0
0
0
5,836
30,264
1,611
1,107
4,059
2,439
3,140
4,263
5,962
7,883
6,447
4,732
9,860
5,151
10,906
17,443
21,826
18,121
18,12121,82617,44310,9065,1519,8604,7326,4477,8835,9624,2633,1402,4394,0591,1071,61130,2645,836000
   > Long-term Liabilities 
0
0
0
56,653
56,653
174,504
382
4,059
62
25
2,217
1,745
829
0
0
30,181
30,461
29,599
29,859
29,569
29,642
29,64229,56929,85929,59930,46130,181008291,7452,21725624,059382174,50456,65356,653000
       Deferred Long Term Asset Charges 
0
0
0
0
0
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,35200000
       Warrants
0
0
0
0
0
349,008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000349,00800000
       Deferred Long Term Liability 
0
0
0
0
257
2,352
0
0
0
238
337
0
0
183
0
0
0
0
0
0
0
0000000183003372380002,3522570000
> Total Stockholder Equity
5,980
0
0
-18,591
-45,462
-106,079
233,360
225,183
216,089
206,519
196,651
188,775
179,085
168,874
280,273
266,973
262,034
243,947
217,202
181,816
155,521
155,521181,816217,202243,947262,034266,973280,273168,874179,085188,775196,651206,519216,089225,183233,360-106,079-45,462-18,591005,980
   Common Stock
0
0
0
0
0
0
4
4
4
4
4
4
4
4
6
6
6
6
6
6
6
666666644444444000000
   Retained Earnings -353,923-325,127-287,973-258,208-237,671-222,798-206,301-193,344-181,734-170,427-157,561-146,851-136,700-127,571-119,222-115,320-53,962-26,965000
   Capital Surplus 
0
0
0
0
0
9,241
352,606
352,981
353,599
354,331
355,173
359,949
361,339
362,860
0
0
0
0
0
0
0
0000000362,860361,339359,949355,173354,331353,599352,981352,6069,24100000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
8,374
65,153
9,241
352,606
352,981
353,599
354,331
355,173
359,949
361,339
362,860
487,077
489,453
499,843
502,313
504,651
506,985
509,423
509,423506,985504,651502,313499,843489,453487,077362,860361,339359,949355,173354,331353,599352,981352,6069,24165,1538,374000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-114,017
Operating Income-114,017-114,017
 
Operating Expense (+$)
Research Development93,798
Selling General Administrative20,219
Selling And Marketing Expenses0
Operating Expense114,017114,017
 
Net Interest Income (+$)
Interest Income14,317
Interest Expense-4,068
Other Finance Cost-0
Net Interest Income10,249
 
Pretax Income (+$)
Operating Income-114,017
Net Interest Income10,249
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-102,329-125,705
EBIT - interestExpense = -102,329
-102,329
-98,261
Interest Expense4,068
Earnings Before Interest and Taxes (EBIT)-98,261-98,261
Earnings Before Interest and Taxes (EBITDA)-98,083
 
After tax Income (+$)
Income Before Tax-102,329
Tax Provision-0
Net Income From Continuing Ops-102,329-102,329
Net Income-102,329
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses114,017
Total Other Income/Expenses Net11,688-10,249
 

Technical Analysis of Acumen Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acumen Pharmaceuticals Inc. The general trend of Acumen Pharmaceuticals Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acumen Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Acumen Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acumen Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.282 < 1.31 < 1.48.

The bearish price targets are: 1.09 > 1.09 > 1.09.

Know someone who trades $ABOS? Share this with them.👇

Acumen Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acumen Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acumen Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acumen Pharmaceuticals Inc. The current macd is 0.01752791.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acumen Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Acumen Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Acumen Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acumen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAcumen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acumen Pharmaceuticals Inc. The current adx is 26.44.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Acumen Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Acumen Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acumen Pharmaceuticals Inc. The current sar is 1.09756107.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Acumen Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acumen Pharmaceuticals Inc. The current rsi is 51.76. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Acumen Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAcumen Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acumen Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acumen Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Acumen Pharmaceuticals Inc Daily Stochastic Oscillator ChartAcumen Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acumen Pharmaceuticals Inc. The current cci is -25.47311277.

Acumen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAcumen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acumen Pharmaceuticals Inc. The current cmo is 1.20192522.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Acumen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAcumen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acumen Pharmaceuticals Inc. The current willr is -57.69230769.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Acumen Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Acumen Pharmaceuticals Inc Daily Williams %R ChartAcumen Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acumen Pharmaceuticals Inc. The current atr is 0.0756008.

Acumen Pharmaceuticals Inc Daily Average True Range (ATR) ChartAcumen Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acumen Pharmaceuticals Inc. The current obv is 19,300,468.

Acumen Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAcumen Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acumen Pharmaceuticals Inc. The current mfi is 28.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acumen Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAcumen Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acumen Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Acumen Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acumen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.763
Ma 20Greater thanMa 501.173
Ma 50Greater thanMa 1001.093
Ma 100Greater thanMa 2001.148
OpenGreater thanClose1.150
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Acumen Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Acumen Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acumen Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acumen Pharmaceuticals Inc

I send you an email if I find something interesting about Acumen Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Acumen Pharmaceuticals Inc.

Receive notifications about Acumen Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.